Tekmira Surges Amid Promise of Ebola Treatment
This article is for subscribers only.
Nov. 4 (Bloomberg) -- Tekmira Pharmaceutical Corp. isleading Ebola-related drug stocks as investors wager theCanadian company’s therapy is among the most promising to combatthe strain of the outbreak that’s sweeping West Africa.
Shares of the Burnaby, British Columbia-based company,which is developing its treatment under a $140 million contractwith the U.S. Defense Department, have advanced 113 percent thisyear, the most among competitors including Sarepta TherapeuticsInc. and BioCryst Pharmaceuticals Inc.